Pan‑TRK
Also known as: TRKA, TRKB, TRKC
Use
Pan‑TRK (clone EPR17341) targets the C‑terminal region of TRK A, B, and C proteins encoded by NTRK1, NTRK2, and NTRK3 respectively. It serves as a screening immunohistochemical assay for the identification of NTRK protein overexpression due to gene fusions. While IHC sensitivity for detecting NTRK fusions is high (95% and above), some discrepant cases (false positives or negatives) exist. It is not recommended for use in certain tumor types (neuroendocrine tumors, GISTs, gliomas, and adult sarcomas) where staining may occur in absence of gene translocation. Positive IHC results should be followed by molecular testing to confirm NTRK gene rearrangement and identify the fusion partner.
Special Instructions
Not provided.
Limitations
Correlation between IHC staining results and molecular confirmation of TRK fusions is moderate; discordant results have been reported. IHC screening is not recommended for neuroendocrine tumors, GISTs, gliomas, or adult sarcomas due to potential non–fusion–related staining.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Formalin‑fixed, paraffin‑embedded (FFPE) tissue block preferred; alternatively, one unbaked, unstained H&E slide (required) plus two to three positively charged unstained slides (4‑5 microns) for each test/antibody ordered. Block and slide identifiers must match requisition.
Storage Instructions
Use cold pack during transport; do not place cold pack in direct contact with specimen. NYS clients: include collection date and time.